Skip to main content

PIK3CA

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Edward Garon, MD
Videos
10/07/2026
Edward B. Garon, MD, MS
Edward Garon, MD, reviews the clinical decision-making behind the management of a patient with EGFR L858R–mutated non–small cell lung cancer, brain metastases, and suspected leptomeningeal disease, highlighting considerations for additional...
Edward Garon, MD, reviews the clinical decision-making behind the management of a patient with EGFR L858R–mutated non–small cell lung cancer, brain metastases, and suspected leptomeningeal disease, highlighting considerations for additional...
Edward Garon, MD, reviews the...
10/07/2026
Oncology
Katherine Peters, MD, PhD
Videos
10/06/2026
Katherine Peters, MD, PhD, discusses results from the phase 2 J201 study evaluating safusidenib in patients with IDH1-mutat glioma, highlighting durable antitumor activity and the expanding clinical development of this targeted therapy before...
Katherine Peters, MD, PhD, discusses results from the phase 2 J201 study evaluating safusidenib in patients with IDH1-mutat glioma, highlighting durable antitumor activity and the expanding clinical development of this targeted therapy before...
Katherine Peters, MD, PhD,...
10/06/2026
Oncology
Ajay Nooka, MD
Videos
10/01/2026
Ajay Nooka, MD
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses...
10/01/2026
Oncology
Sara Hurvitz, MD
Videos
10/01/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses...
10/01/2026
Oncology
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai
Videos
10/01/2026
John Mascarenhas, MD
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a...
10/01/2026
Oncology
Naseema Gangat, MBBS
Videos
09/24/2026
Naseema Gangat, MBBS
Naseema Gangat, MBBS, discusses results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera, highlighting reductions in therapeutic phlebotomy requirements, improvements in patient-reported symptoms, and...
Naseema Gangat, MBBS, discusses results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera, highlighting reductions in therapeutic phlebotomy requirements, improvements in patient-reported symptoms, and...
Naseema Gangat, MBBS, discusses...
09/24/2026
Oncology
Naseema Gangat, MBBS
Videos
09/23/2026
Naseema Gangat, MBBS
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses...
09/23/2026
Oncology
Diana Osorio, MD, MPH, MD Anderson Cancer Center
Videos
09/18/2026
Diana Osorio, MD, MPH
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses...
09/18/2026
Oncology
Geoffrey Ku, MD
Videos
09/08/2026
Geoffrey Ku, MD
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses...
09/08/2026
Oncology
Viktor Grünwald, MD, PhD
Videos
09/02/2026
Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD,...
09/02/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology
News
09/27/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3...
09/27/2026
Oncology
FDA Approval
09/24/2026
Emily Estrada
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the...
09/24/2026
Oncology
News
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology
News
09/24/2026
Emily Estrada
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3...
09/24/2026
Oncology
News
09/24/2026
Emily Estrada
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial...
09/24/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology